07:13 AM EDT, 10/31/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) reported Q3 non-GAAP net income Thursday of $12.46 per diluted share, up from $11.59 a year earlier.
Analysts polled by Capital IQ expected $11.71.
Total revenue for the quarter ended Sept. 30 was $3.72 billion, up from $3.36 billion a year earlier.
Analysts surveyed by Capital IQ expected $3.67 billion.